- Motley Fool
Is Pfizer's Pain Sarepta Therapeutics' Gain? Don't Bet on It.
One company's negative results can increase scrutiny of another's work.
- Investor's Business Daily
Sarepta Therapeutics Scores 90-Plus RS Rating On Muscular Dystrophy Approval
Sarepta Therapeutics had its Relative Strength (RS) Rating upgraded from 68 to 95 Monday. The biotech soared 30% Friday on positive news on its Duchenne Muscular Dystrophy gene therapy. Decades of market research shows that the best stocks often have an 80 or better RS Rating as they begin their biggest runs.
